FOREX.com by StoneX logo

Merck trades lower after 1Q results

Merck KGaA, the chemicals and pharmaceuticals group, posted 1Q net income surged to 458 million euros from 190 million euros in the prior-year period

Global Author
Global Author

Share this:

Merck trades lower after 1Q results – The trend remains bullish
Merck KGaA, the chemicals and pharmaceuticals group, posted 1Q net income surged to 458 million euros from 190 million euros in the prior-year period and adjusted EBITDA rose 27.2% on year to 1.18 billion euros on revenue of 4.37 billion euros, up 16.7%. Regarding full-year outlook, the company said: "Group EBITDA pre is expected to be in a range of between E4.35 billion and E4.85 billion. Owing to strong restrictions of economic life and declining income in the context of the Covid-19 pandemic with correspondingly adverse effects on the businesses, Merck forecasts a merely stable organic development."

From a technical perspective, the bearish gap opened this morning calls for a short term consolidation move. However, the trend remains bullish.  A pennant pattern is taking shape. (Continuation trend pattern).  The daily Relative Strength Index (RSI, 14) is above 50% and is not overbought (<70%).

As long as 95E is support, the bias is bullish. The validation of the pennant pattern would call for a new rise towards 110E and 118.4E.

Alternatively, a break below 95E would negate the bullish view and would call for a reversal down trend with 87.45E as first target.

Market chart demonstrating Merck Trades Lower After 1Q Results. Published in May 2020 by CityIndex

Source: GAIN Capital, TradingView

 

Merck KGaA, the chemicals and pharmaceuticals group, posted 1Q net income surged to 458 million euros from 190 million euros in the prior-year period and adjusted EBITDA rose 27.2% on year to 1.18 billion euros on revenue of 4.37 billion euros, up 16.7%. Regarding full-year outlook, the company said: "Group EBITDA pre is expected to be in a range of between E4.35 billion and E4.85 billion. Owing to strong restrictions of economic life and declining income in the context of the Covid-19 pandemic with correspondingly adverse effects on the businesses, Merck forecasts a merely stable organic development."

From a technical perspective, the bearish gap opened this morning calls for a short term consolidation move. However, the trend remains bullish.  A pennant pattern is taking shape. (Continuation trend pattern).  The daily Relative Strength Index (RSI, 14) is above 50% and is not overbought (<70%).

As long as 95E is support, the bias is bullish. The validation of the pennant pattern would call for a new rise towards 110E and 118.4E.

Alternatively, a break below 95E would negate the bullish view and would call for a reversal down trend with 87.45E as first target.

Market chart demonstrating Merck Trades Lower After 1Q Results. Published in May 2020 by FOREX.com

Source: GAIN Capital, TradingView

 

The complete CFD trading experience

Award-winning platforms, competitive spreads, low commissions and dedicated support.

We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.

Economic calendar

Web Trader platform

Our sophisticated web-based platform is packed with features.

Related articles

S&P 500 forecast: Stocks extend drop as correction risks grow

US and global equity markets have extended Wednesday’s sell-off, with Wall Street opening lower after a weak handover from Asia and Europe. The deterioration in risk appetite has been spreading across global markets. The dollar was firmer, Treasury yields were holding onto yesterday’s gains, while gold, silver and bitcoin were all under pressure alongside equities and major currencies.

StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.

StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.

It's your world. Trade it.